ID

13253

Description

Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT00850382

Lien

https://clinicaltrials.gov/show/NCT00850382

Mots-clés

Versions (1)
  1. 26/01/2016 26/01/2016 -
Détendeur de droits

CC BY-NC 3.0

Téléchargé le

26 janvier 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Acute Myeloid Leukemia (AML) DRKS00003753 NCT00850382

Anglais

Eligibility Acute Myeloid Leukemia (AML) NCT00850382

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
core binding factor (cbf) aml with molecular diagnosis of runx1-runx1t1 fusion transcript resulting from t(8;21)(q22;q22) (or a variant form) or of cbfb-myh11 fusion transcript resulting from inv(16)(p13.1q22)/t(16;16)(p13.1;q22) as assessed in one of the central amlsg reference laboratories.
Description

AML

Type de données

boolean

Alias
UMLS CUI [1]
C0023467
age ≥ 18; there is no upper age limit.
Description

age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
no prior chemotherapy for leukemia except hydroxyurea for up to 5 days during the diag-nostic screening phase.
Description

chemotherapy

Type de données

boolean

Alias
UMLS CUI [1]
C0392920
non-pregnant and non-nursing. due to the unknown teratogenic potential of dasatinib in humans, pregnant or nursing patients may not be enrolled. women of childbearing poten-tial (wocbp) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 miu/ml within 72 hours prior to registration. women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control - one highly effective method (e.g., iud, hormonal, tubal ligation, or partner's vasectomy), and one additional effective method (e.g., latex condom, diaphragm, or cervical cap) - at the same time, at least four weeks before she begins dasatinib therapy. "women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months.
Description

pregnancy, lactation and contraception

Type de données

boolean

Alias
UMLS CUI [1]
C0006147
UMLS CUI [2]
C0032961
UMLS CUI [3]
C0700589
men must agree not to father a child and must use a latex condom during any sexual con-tact with women of childbearing potential while taking dasatinib and for 4 weeks after therapy is stopped, even if they have undergone a successful vasectomy.
Description

contraception

Type de données

boolean

Alias
UMLS CUI [1]
C0700589
signed written informed consent
Description

informed consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
performance status who >2
Description

who performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1298650
pulmonary edema and/or pleural/pericardial effusion within 14 days of day 1. if edema/effusion resolves to ctc grade ≤ 1, patients can be treated with dasatinib.
Description

pulmonary edema and/or pleural/pericardial effusion

Type de données

boolean

Alias
UMLS CUI [1]
C0034063
UMLS CUI [2]
C0032227
patients with ejection fraction < 50% by echocardiography within 14 days of day 1
Description

ejection fraction

Type de données

boolean

Alias
UMLS CUI [1]
C0232174
organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, ast or ap >2.5x upper normal serum level; heart failure nyha iii/iv; severe obstructive or restrictive ventilation disorder)
Description

organ insufficiency

Type de données

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C1278039
UMLS CUI [3]
C0002594
UMLS CUI [4]
C1275491
UMLS CUI [5]
C0024115
uncontrolled infection
Description

infection

Type de données

boolean

Alias
UMLS CUI [1]
C0009450
severe neurological or psychiatric disorder interfering with ability of giving an informed consent
Description

neurological or psychiatric disorder interfering with ability of giving an informed consent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
known positive for hiv
Description

HIV

Type de données

boolean

Alias
UMLS CUI [1]
C0019682
bleeding disorder independent of leukemia
Description

bleeding disorder

Type de données

boolean

Alias
UMLS CUI [1]
C0005779
no consent for registration, storage and processing of the individual disease-characteristics and course
Description

no consent for registration, storage and processing of the individual disease-characteristics and course

Type de données

boolean

Alias
UMLS CUI [1]
C1511481
Retour au début de la page

Similar models

Eligibility Acute Myeloid Leukemia (AML) NCT00850382

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
AML
Item
core binding factor (cbf) aml with molecular diagnosis of runx1-runx1t1 fusion transcript resulting from t(8;21)(q22;q22) (or a variant form) or of cbfb-myh11 fusion transcript resulting from inv(16)(p13.1q22)/t(16;16)(p13.1;q22) as assessed in one of the central amlsg reference laboratories.
boolean
C0023467 (UMLS CUI [1])
age
Item
age ≥ 18; there is no upper age limit.
boolean
C0001779 (UMLS CUI [1])
chemotherapy
Item
no prior chemotherapy for leukemia except hydroxyurea for up to 5 days during the diag-nostic screening phase.
boolean
C0392920 (UMLS CUI [1])
pregnancy, lactation and contraception
Item
non-pregnant and non-nursing. due to the unknown teratogenic potential of dasatinib in humans, pregnant or nursing patients may not be enrolled. women of childbearing poten-tial (wocbp) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 miu/ml within 72 hours prior to registration. women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control - one highly effective method (e.g., iud, hormonal, tubal ligation, or partner's vasectomy), and one additional effective method (e.g., latex condom, diaphragm, or cervical cap) - at the same time, at least four weeks before she begins dasatinib therapy. "women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months.
boolean
C0006147 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
contraception
Item
men must agree not to father a child and must use a latex condom during any sexual con-tact with women of childbearing potential while taking dasatinib and for 4 weeks after therapy is stopped, even if they have undergone a successful vasectomy.
boolean
C0700589 (UMLS CUI [1])
informed consent
Item
signed written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
who performance status
Item
performance status who >2
boolean
C1298650 (UMLS CUI [1])
pulmonary edema and/or pleural/pericardial effusion
Item
pulmonary edema and/or pleural/pericardial effusion within 14 days of day 1. if edema/effusion resolves to ctc grade ≤ 1, patients can be treated with dasatinib.
boolean
C0034063 (UMLS CUI [1])
C0032227 (UMLS CUI [2])
ejection fraction
Item
patients with ejection fraction < 50% by echocardiography within 14 days of day 1
boolean
C0232174 (UMLS CUI [1])
organ insufficiency
Item
organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, ast or ap >2.5x upper normal serum level; heart failure nyha iii/iv; severe obstructive or restrictive ventilation disorder)
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0002594 (UMLS CUI [3])
C1275491 (UMLS CUI [4])
C0024115 (UMLS CUI [5])
infection
Item
uncontrolled infection
boolean
C0009450 (UMLS CUI [1])
neurological or psychiatric disorder interfering with ability of giving an informed consent
Item
severe neurological or psychiatric disorder interfering with ability of giving an informed consent
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
HIV
Item
known positive for hiv
boolean
C0019682 (UMLS CUI [1])
bleeding disorder
Item
bleeding disorder independent of leukemia
boolean
C0005779 (UMLS CUI [1])
no consent for registration, storage and processing of the individual disease-characteristics and course
Item
no consent for registration, storage and processing of the individual disease-characteristics and course
boolean
C1511481 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial